MEDCu Technologies

Company Overview

Snapshot

Founded in September 2016 by Danny Lustiger and Gadi Borkow, MEDCu Technologies operates with 11–50 employees. The company is currently in a Pre-Funding stage. In November 2018, the company received FDA Premarket Notification K180643 for its Medcu Antibacterial Wound Dressings with Copper-oxide.

Business overview

MEDCu Technologies is a biotech company focused on developing cost-effective antimicrobial wound dressings that incorporate copper microparticles. Its core product, the MedCu Wound Dressing, features an internal absorbent layer and nonwoven external layers impregnated with copper particles, designed to provide a barrier against bacterial contamination while supporting the healing process. These nonirritating and nonsensitizing dressings are available in various configurations and are suitable for acute, diabetic, and chronic wounds. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Biomaterials & Tissue Engineering, leveraging over 15 years of research protected by more than 30 patents worldwide.

Strategic signal

In October 2021, news highlighted MEDCu Technologies' innovative Israeli copper dressing as a significant aid in curing diabetic wounds. This signals the company's potential to address critical unmet needs in wound care, particularly for chronic conditions like diabetes, and validates the therapeutic efficacy of its copper-based technology in a major health challenge.

Company Intelligence Q&A

What is the primary focus of MEDCu Technologies?

MEDCu Technologies focuses on developing and commercializing copper-based antimicrobial wound dressings designed to prevent bacterial contamination and promote healing for various types of wounds, including acute, diabetic, and chronic conditions.

When was MEDCu Technologies founded and by whom?

MEDCu Technologies was founded in September 2016 by Danny Lustiger and Gadi Borkow.

What is the key technology behind MEDCu's products?

The company's key technology involves incorporating copper microparticles into wound dressings. This approach is based on over 15 years of research and is protected by more than 30 patents globally, aiming to leverage copper's antimicrobial properties.

Has MEDCu Technologies received any regulatory clearances for its products?

Yes, in November 2018, MEDCu Technologies received FDA Premarket Notification K180643 for its Medcu Antibacterial Wound Dressings with Copper-oxide.

What markets does MEDCu Technologies target with its wound care products?

MEDCu Technologies targets the healthcare market, specifically addressing the needs of patients with acute, diabetic, and chronic wounds, leveraging its copper-based dressings to improve healing outcomes.